Abstract
Emerging evidence indicates that C-X-C chemokine receptor type 4 (CXCR4) is a candidate oncogene in several types of human tumors including renal cell carcinoma (RCC). We conducted a meta-analysis to quantitatively evaluate the association of CXCR4 expression with the incidence of RCC and clinicopathological characteristics. We searched PubMed, Embase, and ISI Web of Knowledge to identify studies written in English. Methodological quality of the studies was also evaluated. Odds ratio and hazard ratio were calculated and summarized. Final analysis was performed of 994 RCC patients from 11 eligible studies. We observed that CXCR4 expression was significantly higher in RCC than in normal renal tissues. CXCR4 expression was not found to be associated with sex status or clinical staging. However, CXCR4 expression was clearly associated with Fuhrman grading, metastatic status, and overall survival in RCC patients. The results of this meta-analysis suggest that CXCR4 expression is associated with an increased risk and worsen survival in RCC patients. The aberrant CXCR4 expression plays an important role in the carcinogenesis and metastasis of RCC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
